Osso VR has raised $27 million in a series B financing led by GSR Ventures. The funds will be used to accelerate expansion of its library and virtual reality (VR)-powered surgical training and assessment platform.

LONDON – Nerre Therapeutics Ltd. will have another go at delivering proof of efficacy for its chronic cough treatment, after raising £20 million (US$27.6 million) in a series B2 round.

Just five days after raising $105 million in a series E financing round, RNA interference therapeutics specialist Sirnaomics Inc. obtained another IND approval from the FDA for its dual-targeting small interfering RNA (siRNA) inhibitor STP-707 to start a basket study in oncology. Sirnaomics’ CEO Patrick Lu told BioWorld in an exclusive interview that an I.V. administration of STP-707 will be tested to tackle solid cancers that may have metastasized into other potential areas or tissue types in the body.

PERTH, Australia – Startup Currus Biologics Pty Ltd. has launched with a AU$10 million (US$7.5 million) series A round with the mission of improving the success of CAR T-cell therapies against solid tumors such as breast, ovarian and pancreatic cancers.

HONG KONG – Hummingbird Bioscience Pte. Ltd. has raised $125 million in a series C financing to further investments in its early stage pipeline, as well as support the clinical development of its two lead oncology programs.

TORONTO – Audioptics Medical Inc. has raised a C$1.9 million (US$1.5 million) seed investment round for development of a device that visualizes and assesses the structures of the middle ear to help patients avoid surgery for conductive hearing loss. Audioptics Medical CEO Dan MacDougall told BioWorld the investment marks a major step in his company’s path towards commercial development of its flagship product, the Ossiview Middle Ear Imaging system.

Neuroelectrics Inc. garnered $17.5 million in a series A fundraising round led by the Morningside Group of Hong Kong. The Cambridge, Mass. and Barcelona-based brain stimulation company plans to use the funds primarily to advance its pivotal trial of the Starstim system in refractory focal epilepsy and its at-home feasibility study in refractory major depressive disorder and related infrastructure, Neuroelectrics co-founder and CEO Ana Maiques told BioWorld. Supportive infrastructures for the trials include brain modeling, the platform for remote montage delivery, and clinical and regulatory resources.

LONDON – Antibody prospecting specialist Alchemab Therapeutics Ltd. has raised £60 million (US$82.7 million) in a series A round, to take programs in neurodegenerative diseases and cancer into the clinic.

The newly renamed Hutchmed (China) Ltd., previously known as Hutchison China Meditech Ltd. (Chi-Med), plans to sell $100 million of its American depository shares at $30.50 per ADS in a private placement to funds affiliated with Baring Private Equity Asia.

The newly renamed Hutchmed (China) Ltd., previously known as Hutchison China Meditech Ltd. (Chi-Med), plans to sell $100 million of its American depository shares at $30.50 per ADS in a private placement to funds affiliated with Baring Private Equity Asia.